Hepatocellular Carcinoma | Disease Landscape & Forecast | G7 | 2022

Hepatocellular carcinoma remains a challenging disease with a complex underlying etiology. While angiogenesis inhibitors including Nexavar (Bayer / Amgen), Stivarga (Bayer), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis / Ipsen / Takeda), and Cyramza (Eli Lilly) have been central to the treatment of advanced disease, the market is set to witness a substantial change within the next 10 years driven by the 2020 approval of Tecentriq (Roche / Genentech) plus bevacizumab, the FDA approval of Imfinzi plus Imjudo (AstraZeneca) and the anticipated entry of novel emerging immune checkpoint inhibitor-based combinations. The anticipated uptake of these premium-priced regimens and their expected label expansion into the untapped early-stage setting will drive robust growth of the hepatocellular carcinoma market, where identified unmet needs remain to offer further opportunities for effective therapy development.

Questions answered

  • What are the current therapies for hepatocellular carcinoma, and what are the main unmet needs?
  • What is the size of market-relevant drug-treatable populations, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent and forecast drug approvals on the various subpopulations of hepatocellular carcinoma? What are interviewed experts’ insights on key existing and emerging agents?
  • What are the key factors driving or constraining market growth?

Content highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 19 country-specific interviews with thought-leading medical oncologists.

Key companies: Bayer HealthCare / Amgen / Onyx, Bristol Myers Squibb / Ono Pharmaceutical, Merck & Co., Eisai, Exelixis / Ipsen, Eli Lilly, Roche / Genentech, AstraZeneca.

Key drugs: Nexavar, Lenvima, Stivarga, Cabometyx, Cyramza, Avastin, Tecentriq, Opdivo, Yervoy, Keytruda, Imfinzi, Imjudo.

Population segments in the market forecast: early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.

Emerging therapies: Phase III/PR: 4 drugs; coverage of select Phase I and Phase II products.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report

launch Related Market Assessment Reports